Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns

Infographics: things to know about AMR

FACT: Antimicrobial resistance (AMR): when microbes, like bacteria, evolve to survive exposure to antimicrobial medicines, such as antibiotics, used for treatment or prevention (prophylaxis). This makes antimicrobials less effective and infections more difficult to treat. MSF
AMR: One of the most significant global public health threats of our time. By 2050, AMR is estimated to contribute to 8.2 million deaths worldwide.. MSF
FACT: Humanitarian settings compound the AMR crisis. Natural disasters. Displacement. Overcrowded places. Conflict. Collapsed health systems. MSF
FACT: People in low- and middle-income countries experience the highest rates of AMR globally, with limited access to diagnostic tools and microbiology capacities to identify AMR and medicines to treat AMR. MSF
MSF address AMR through dedicated prevention, detection, and response efforts: +20 countries, +50 projects. MSF's AMR response package includes infection prevention and control, antibiotic stewardship, and providing access to microbiology lab-based diagnostics and surveillance. MSF
CONCRETE ACTION IS NEEDED. Ensure equitable access to existing diagnostic tools, microbiology capacities, legacy and new lifesaving antibiotics, AND increase research and development for low-resource and humanitarian settings, where it is most needed. MSF

Read, watch, share

Statement |
02 May 2016
Antimicrobial resistance Research and development

MSF at WHO's Open-Ended Meeting on CEWG - Agenda Item 5 (a-d)

3 min
Statement |
28 January 2016
Antimicrobial resistance

138th WHO EB - Agenda Item 8.5: Global Action Plan on Antimicrobial Resistance

MSF134504 Photography by Vivian Lee
Press release
Press release |
16 November 2015
Antimicrobial resistance

MSF urges better diagnostics, education to address antimicrobial resistance threat

3 min
Simphiwe holds his medication, he takes up to 26 pills a day to treat XDR-TB. Here he holds his morning selection, which includes delamanid, one of the newest DR-TB drugs, which Simphiwe is taking for the first time today. Photograph by Sydelle Willow Smith
Opinion article
Opinion article |
18 June 2015
Research and development

A Global Biomedical R&D Fund and Mechanism for Innovations of Public Health Importance

MSF Doctor Joan providing a consultation to Nischaya, an XDR-TB patient, in the MSF clinic in Mumbai, 2016 Photograph by Atul Loke
Press release
Press release |
13 May 2015
Tuberculosis

MSF responds to TB Alliance announcement of the Nix-TB clinical trial

3 min
Joanne Liu (International President), Ronald Kremer (OCA Health Advisor) and Brice dele Vigne visited the ebola treatment centre in Kailahun, Sierra Leone on August 2011 Photograph by P.K. Lee
Press release
Press release |
11 May 2015
Research and development

MSF and DNDi Join Call for a Biomedical Research and Development Fund and Mechanism to Meet Pressing Global Health Needs

4 min
Statement |
29 January 2015
Antimicrobial resistance

136th WHO EB - MSF intervention on Antimicrobial resistance

Statement |
30 April 2014
Antimicrobial resistance

MSF reponse to WHO report on antimicrobial resistance

1 min
  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury